Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Pancreatic tumors use clotting pathway to build immune shields, study finds (opens in a new tab)

medicalxpress.com · 2026-09-13

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 3 supported
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Three of five claims match the study. This overall rating is based only on the claims we could check. Two claims the study doesn't address.

  • 3 supported
  • 2 not covered
Open claim evidence
3
Source paper

Source layer

The 3 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredIn laboratory and other preclinical models, even when just 5% of implanted pancreatic cancer cells produced PAI1, they could reshape the immune environment by increasing immune-suppressing macrophages and reducing activated T cells nearby.View evidenceHide evidence

As statedjust 5%

Why this verdict

The direction of the biology is supported at abstract level—PAI1/PAI2-expressing tumour cells can reshape local immune niches with macrophage enrichment/programming and T-cell exclusion. However, the specific quantitative claim that only 5% of implanted pancreatic cancer cells produced PAI1 is not present in the abstract-level profile, nor are the detailed experimental conditions needed to verify that magnitude.

1

Study evidence

SERPINE1 (PAI1) and SERPINB2 (PAI2) were identified as dominant regulators of tumour microenvironment control and immune evasion in PDAC.

“We identify SERPINE1 ... and SERPINB2 ... as dominant regulators of tumour microenvironment control and immune evasion.”
Claim 2 of 5Not coveredIn multiple preclinical models, removing the genes responsible for PAI1 or PAI2, or blocking the pathway with an experimental drug, reduced immune suppression, slowed tumor growth, and significantly improved the effectiveness of anti-PD-1 immunotherapy.View evidenceHide evidence

As statedsignificantly improved

Why this verdict

The abstract-level profile supports that genetic loss of Serpine1 or Serpinb2, or pharmacologic inhibition of PAI1 or CD18, improved tumour control in mice and synergized with anti-PD-1. But the story adds details not verifiable from the abstract profile, including 'multiple preclinical models,' 'slowed tumor growth' as the specific endpoint, and 'significantly' improved effectiveness; the profile explicitly lacks model details, quantitative outcomes, sample sizes, and statistical support.

1

Study evidence

SERPINE1 (PAI1) and SERPINB2 (PAI2) were identified as dominant regulators of tumour microenvironment control and immune evasion in PDAC.

“We identify SERPINE1 ... and SERPINB2 ... as dominant regulators of tumour microenvironment control and immune evasion.”
2

Study evidence

Loss of Serpine1 or Serpinb2, or pharmacological inhibition of PAI1 or CD18, improves tumour control in mice and synergizes with anti-PD-1.

“Loss of Serpine1 or Serpinb2, or pharmacological inhibition of PAI1 or CD18, improves tumour control in mice and synergizes with anti-PD-1.”
Claim 3 of 5SupportedResearchers at the Icahn School of Medicine at Mount Sinai found that small populations of pancreatic cancer cells can create localized immune-protective niches that shield tumors from immune attack.View evidenceHide evidence

As statedsmall populations

Why this verdict

The abstract-level profile supports the core claim that rare/small SERPINE1/SERPINB2-expressing PDAC subpopulations can organize localized immunosuppressive niches. The paper profile describes tumour-intrinsic regulators that stabilize fibrin-rich ECM niches, retain/program immunosuppressive macrophages, and exclude cytotoxic T cells. Human patient-tumour evidence is spatial/ex-vivo, while causal support comes mainly from preclinical perturbation models.

1

Study evidence

Early gene-driven remodelling of local immune neighbourhoods precedes late-stage spatial clonal dominance in PDAC, as revealed by Perturb-map.

“using Perturb-map spatial functional genomics, we determine how different genes shape the growth and cellular environments of PDAC clones across space and time.”
2

Study evidence

SERPINE1 (PAI1) and SERPINB2 (PAI2) were identified as dominant regulators of tumour microenvironment control and immune evasion in PDAC.

“We identify SERPINE1 ... and SERPINB2 ... as dominant regulators of tumour microenvironment control and immune evasion.”
Claim 4 of 5SupportedThe findings, published in Nature, show that a small number of pancreatic cancer cells activate genes that stabilize fibrin, a protein involved in blood clotting, and use this wound-healing system to build a protective environment that prevents cancer-fighting immune cells from reaching pancreatic tumors.View evidenceHide evidence

As stateda small number

Why this verdict

The scientific substance is supported: the profile says rare SERPINE1/SERPINB2-expressing PDAC subpopulations form immunosuppressive niches and that PAI1/PAI2 promote stabilization of fibrin-rich extracellular matrix niches that exclude cytotoxic T cells. The profile does not independently verify the journal venue, and the wording 'wound-healing system' is an interpretation of the fibrin/clotting-related biology rather than a directly profiled phrase.

1

Study evidence

SERPINE1 (PAI1) and SERPINB2 (PAI2) were identified as dominant regulators of tumour microenvironment control and immune evasion in PDAC.

“We identify SERPINE1 ... and SERPINB2 ... as dominant regulators of tumour microenvironment control and immune evasion.”
2

Study evidence

Multimodal spatial analysis of human PDAC tumours revealed that immunosuppressive niches form around rare SERPINE1- and SERPINB2-expressing tumour subpopulations, and these niches are dominated by SPP1+/MARCO+ macrophages.

“Multimodal spatial analysis of patient tumours revealed that immunosuppressive niches form around rare SERPINB2- and SERPINE1-expressing PDAC subpopulations, dominated by SPP1+/MARCO+ macrophages.”
Claim 5 of 5SupportedThe investigators identified PAI1 and PAI2 as key drivers of immune protection; these proteins promote fibrin buildup, attract and retain macrophages, and reduce nearby activated T cells.View evidenceHide evidence

Why this verdict

The profile identifies SERPINE1/PAI1 and SERPINB2/PAI2 as dominant regulators of tumour microenvironment control and immune evasion. It supports the mechanistic chain that these serpins promote fibrin-rich ECM niche stabilization, macrophage retention/programming toward immunosuppressive states, and exclusion of cytotoxic T cells. The story’s 'activated T cells' wording is close but less specific than the profile’s 'cytotoxic T cells.'

1

Study evidence

Early gene-driven remodelling of local immune neighbourhoods precedes late-stage spatial clonal dominance in PDAC, as revealed by Perturb-map.

“using Perturb-map spatial functional genomics, we determine how different genes shape the growth and cellular environments of PDAC clones across space and time.”
2

Study evidence

SERPINE1 (PAI1) and SERPINB2 (PAI2) were identified as dominant regulators of tumour microenvironment control and immune evasion in PDAC.

“We identify SERPINE1 ... and SERPINB2 ... as dominant regulators of tumour microenvironment control and immune evasion.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The paper’s organizing method is Perturb-map spatial functional genomics, used to connect tumour-intrinsic gene perturbations with PDAC clone growth and local immune neighbourhoods across space and time.

    The story mentions spatial transcriptomics and laboratory models, but it does not capture the specific Perturb-map pooled spatial functional genomics design or the paper’s emphasis on mapping perturbations across space and time.

    From Perturb-map spatial functional genomics (pooled perturbation with spatial readout, in vivo PDAC)

  • The abstract reports early gene-driven remodelling of local immune neighbourhoods preceding late-stage spatial clonal dominance.

    The story focuses on immune-protective niches and therapeutic implications, but does not mention the temporal finding that immune-neighbourhood remodelling precedes later spatial clonal dominance.

    From Perturb-map spatial functional genomics (pooled perturbation with spatial readout, in vivo PDAC)

4 things the story did carry across
  • SERPINE1/PAI1 and SERPINB2/PAI2 are dominant regulators that stabilize fibrin-rich ECM niches, retain/program immunosuppressive macrophages, and exclude cytotoxic T cells.
  • Mouse intervention experiments found that Serpine1/Serpinb2 loss or pharmacologic inhibition of PAI1 or CD18 improved tumour control and synergized with anti-PD-1.
  • Human PDAC evidence comes from ex-vivo multimodal spatial profiling showing rare SERPINE1/SERPINB2-expressing tumour subpopulations associated with SPP1+/MARCO+ macrophage-dominated niches.
  • Translation to patients is not established: most functional and therapeutic causal evidence is preclinical mouse work, while human-tumour evidence is spatial association rather than patient-treatment evidence.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalMap how tumour-intrinsic gene perturbations shape PDAC clone growth and local immune neighbourhoods across space and time using Perturb-map spatial functional genomics.Perturb-map spatial functional genomics (pooled perturbation with spatial readout, in vivo PDAC)Expand

In plain English

Using an in vivo Perturb-map pooled spatial functional genomics screen in PDAC, the study maps how tumour-intrinsic gene perturbations drive early local immune neighbourhood remodelling that precedes later spatial clonal dominance and identifies SERPINE1 and SERPINB2 as key regulators of immunosuppressive, fibrin-rich niches that exclude cytotoxic T cells and program macrophages.

Key findings

  • Early gene-driven remodelling of local immune neighbourhoods precedes late-stage spatial clonal dominance in PDAC, as revealed by Perturb-map.
  • SERPINE1 and SERPINB2 are identified as dominant regulators of tumour microenvironment control and immune evasion.
“using Perturb-map spatial functional genomics, we determine how different genes shape the growth and cellular environments of PDAC clones across space and time.”
What this piece can’t prove

4 further details could not be confirmed from the summary.

2in vivo animalEstablish SERPINE1/PAI1 and SERPINB2/PAI2 as dominant regulators that create fibrin-rich ECM niches which retain/programme immunosuppressive macrophages and exclude cytotoxic T cells (mechanistic niche model).Perturb-map spatial functional genomics in PDAC with in vivo validation and multimodal spatial analysis of patient tumoursExpand

In plain English

Abstract reports that SERPINE1 (PAI1) and SERPINB2 (PAI2) act as dominant, cancer-cell-derived regulators of local tumour microenvironments in PDAC by stabilizing fibrin-rich extracellular matrix (ECM) niches that spatially retain and program macrophages toward immunosuppressive states while excluding cytotoxic T cells; genetic loss or pharmacologic inhibition of these serpins (or inhibition of CD18) improves tumour control in mice and synergises with anti-PD-1; multimodal spatial analysis of patient tumours indicates rare SERPINE1/SERPINB2-expressing PDAC subpopulations are associated with SPP1+/MARCO+ immunosuppressive macrophage niches.

Key findings

  • SERPINE1 (PAI1) and SERPINB2 (PAI2) were identified as dominant regulators of tumour microenvironment control and immune evasion in PDAC.
  • These serpins promote stabilization of fibrin-rich extracellular matrix niches that spatially retain and programme macrophages toward immunosuppressive states while excluding cytotoxic T cells.
“We identify SERPINE1 ... and SERPINB2 ... as dominant regulators of tumour microenvironment control and immune evasion.”
What this piece can’t prove
  • Abstract does not provide effect sizes, sample sizes, statistical significance, or detailed assay protocols for ECM, macrophage programming, or T cell exclusion measurements.

3 further details could not be confirmed from the summary.

3in vivo animalTest therapeutic vulnerability: genetic loss or pharmacologic inhibition of PAI1 or CD18 improves tumour control in mice and synergizes with anti-PD-1.in vivo therapeutic testingExpand

In plain English

Abstract reports that in mouse pancreatic ductal adenocarcinoma models, genetic loss of Serpine1 or Serpinb2, or pharmacologic inhibition of PAI1 or CD18, improved tumour control and synergized with anti-PD-1 immunotherapy. The abstract does not provide numerical effect sizes or detailed experimental parameters.

Key findings

  • Loss of Serpine1 or Serpinb2, or pharmacological inhibition of PAI1 or CD18, improves tumour control in mice and synergizes with anti-PD-1.
“Loss of Serpine1 or Serpinb2, or pharmacological inhibition of PAI1 or CD18, improves tumour control in mice and synergizes with anti-PD-1.”
What this piece can’t prove
  • Key experimental details missing from abstract: exact mouse PDAC model(s), genetic manipulation method, identities and dosing regimens of pharmacologic inhibitors, route of administration, treatment timing, sample sizes, blinding/randomization, and endpoint definitions.

2 further details could not be confirmed from the summary.

4ex vivo humanValidate in human PDAC that immunosuppressive niches form around rare SERPINE1/SERPINB2-expressing tumour subpopulations with SPP1+/MARCO+ macrophages using multimodal spatial profiling.ex vivo human spatial profilingExpand

In plain English

Multimodal spatial profiling of human PDAC tumours (ex‑vivo) identified rare tumour subpopulations expressing SERPINE1 and SERPINB2 around which localized immunosuppressive niches form; these niches were dominated by SPP1+/MARCO+ macrophages, indicating spatial association between tumour-intrinsic SERPIN expression and a macrophage immunosuppressive state.

Key findings

  • Multimodal spatial analysis of human PDAC tumours revealed that immunosuppressive niches form around rare SERPINE1- and SERPINB2-expressing tumour subpopulations, and these niches are dominated by SPP1+/MARCO+ macrophages.
“Multimodal spatial analysis of patient tumours revealed that immunosuppressive niches form around rare SERPINB2- and SERPINE1-expressing PDAC subpopulations, dominated by SPP1+/MARCO+ macrophages.”
What this piece can’t prove
  • Abstract provides no information on patient/sample numbers, cohort selection, or representativeness of the identified rare SERPIN-expressing subpopulations.
  • Results describe spatial associations in ex‑vivo tissue; causal inference and links to patient-level clinical outcomes are not addressed in this unit.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 35 candidate papers

Candidate

163P Combinatorial drug screen identifies therapeutic vulnerabilities of pancreatic cancer subtypes

ESMO Open · 2026 · Crossref

Source (opens in a new tab)
Candidate

Digital Diplomacy and the Changing Nature of International Relations | Meritorious Journal of Social Sciences and Management

Scholarly Journal · 2026 · Crossref

Source (opens in a new tab)

And 29 more candidates considered.